Which Supplements May Increase Deep Sleep (N3)? A Research Review

Introduction Deep sleep (stage N3) is the slow-wave, high-amplitude phase of non-REM sleep associated with memory consolidation, synaptic recalibration, growth-hormone pulses, and next-day restoration. Many people who wake unrefreshed wonder whether supplements can increase time spent in N3. This focused review maps what research suggests about supplements and deep sleep, and how these approaches compare with cognitive behavioral therapy for insomnia (CBT-I).

A quick primer on sleep architecture

• N1: Light “dozing” sleep as you transition from wakefulness.
• N2: Stable non-REM sleep; sleep spindles and K-complexes dominate.
• N3: Deep, slow-wave sleep (SWS). Hardest to wake from; often front-loaded in the first third of the night.
• REM: Vivid dreaming and memory processing; concentrated more in the second half of the night.

Changes to any one stage typically shift the others because sleep is organized in cycles of roughly 90 minutes. Polysomnography (PSG) is the gold standard for measuring stages. Consumer wearables estimate stages but show variable accuracy versus PSG; results for N3 and REM can be off at the individual-night level (Evidence: moderate; de Zambotti 2019, Sleep; Chinoy 2021, Sleep).

Supplements and N3: What the evidence shows Below, each claim is labeled with an evidence level: strong, moderate, emerging, or traditional.

Magnesium (including magnesium glycinate): hints, but limited architecture data

• What research suggests: Magnesium is involved in GABAergic signaling and NMDA receptor modulation, which could theoretically favor deeper sleep. Small randomized trials in older adults with insomnia found improvements in sleep efficiency and subjective quality, but typically did not report reliable increases in N3 on PSG. Most studies used mixed or oxide/aspartate forms; data on magnesium glycinate specifically and its effect on deep sleep are sparse. (Abbasi 2012, J Res Med Sci; Cao 2018, Nutrients review).
• Takeaway for N3: Evidence for a direct increase in deep sleep is limited; benefits, when present, appear more global (sleep quality, efficiency) than stage-specific. Evidence: emerging.

Glycine: thermoregulatory and subjective benefits; architecture effects remain tentative

• What research suggests: Bedtime glycine may modestly reduce core body temperature and improve next-day alertness in people with sleep complaints. Randomized crossover trials reported better subjective sleep quality and less fatigue; small PSG-based work suggests possible subtle shifts (e.g., shortened sleep latency and trends toward more slow-wave activity), but findings are not consistent across studies. (Bannai & Kawai 2012, J Pharmacol Sci; Yamadera 2007, Sleep Biol Rhythms; Peuhkuri 2012, Nutrients review).
• Takeaway for N3: Potential but unconfirmed effects on slow-wave sleep; more rigorous PSG trials are needed. Evidence: moderate for subjective sleep quality; emerging for N3.

Melatonin: strong for sleep onset and circadian timing, not for deep sleep per se

• What research suggests: Meta-analyses show melatonin reliably reduces sleep onset latency and modestly increases total sleep time and perceived sleep quality, particularly when circadian phase is delayed. Effects on sleep architecture (including N3) are small or inconsistent in adults without circadian disorders. (Ferracioli-Oda 2013, PLoS One; Auld 2017, Sleep Med Rev).
• Takeaway for N3: Use is best conceptualized for sleep timing and initiation; not a targeted deep-sleep enhancer. Evidence: strong for onset/circadian; limited for N3.

Tart cherry juice: small increases in total sleep time; architecture unclear

• What research suggests: Trials in adults (including those with insomnia) report modest increases in total sleep time and sleep efficiency, possibly via melatonin and polyphenols with anti-inflammatory effects. Most studies did not assess PSG-defined stages; specific effects on N3 are unknown. (Pigeon 2010, J Med Food; Howatson 2012, Eur J Nutr; Losso 2018, Eur J Nutr).
• Takeaway for N3: May help overall sleep duration and continuity; no clear evidence it increases deep sleep proportion. Evidence: moderate for total sleep time; unknown for N3.

Apigenin (commonly from chamomile): promising mechanisms, limited human staging data

• What research suggests: Apigenin is a flavone that interacts with GABA-A receptors in preclinical work. Small human trials of chamomile extract show improvements in insomnia severity and sleep quality; PSG-defined changes, including N3, are rarely reported. (Zick 2011, Phytomedicine; Chang & Chen 2016, J Adv Nurs; Srivastava 2010, Mol Med Rep review).
• Takeaway for N3: Human evidence for stage-specific effects is preliminary. Evidence: emerging.

Valerian root: mixed outcomes; little consistent effect on N3

• What research suggests: Systematic reviews find heterogeneous trials with variable quality; some show small improvements in subjective sleep, while objective measures, including PSG stages, are often unchanged. (Leach & Page 2015, Cochrane Review; Taibi 2009, Sleep Med Rev).
• Takeaway for N3: Not reliably associated with increased deep sleep. Evidence: moderate for subjective outcomes; limited for N3.

Passionflower (Passiflora incarnata): small trials, subjective benefits

• What research suggests: Limited RCTs show improvements in subjective sleep quality over short durations; PSG data are scarce. (Ngan & Conduit 2011, Phytother Res; Lee 2021, Integr Med Res review).
• Takeaway for N3: No convincing evidence for stage-specific effects. Evidence: emerging/traditional.

Jujube seed (Ziziphus jujuba var. spinosa; Suan Zao Ren): traditional calming herb with early clinical signals

• What research suggests: In East Asian medicine, Suan Zao Ren is used to “quiet the spirit,” aligning with modern findings of GABAergic modulation in preclinical studies. Meta-analyses and small RCTs of Suan Zao Ren–based formulas report improvements in insomnia severity and sleep quality; PSG staging, including N3, is rarely captured. (Cao 2020, Medicine (Baltimore); Chen 2014, Evid Based Complement Alternat Med).
• Takeaway for N3: Traditional use aligns with relaxation and consolidation, but stage-specific human evidence is lacking. Evidence: traditional with emerging clinical support.

How do these approaches compare with CBT-I?

• CBT-I is considered first-line for chronic insomnia by major sleep societies. Meta-analyses show robust improvements in sleep onset latency, wake after sleep onset, and sleep efficiency, with benefits that often persist months to years. While most CBT-I studies focus on symptoms and continuity rather than architecture, improved consolidation may indirectly support healthier proportions of N3 and REM across the night. (Trauer 2015, Ann Intern Med; Wu 2015, JAMA Intern Med; Edinger & Means 2020, Chest guideline). Evidence: strong.
• In contrast, supplement effects tend to be smaller, more variable, and less consistent across individuals—especially for changing specific stages like N3. Evidence: moderate overall for subjective sleep outcomes; limited for stage-targeting.

Measurement matters: PSG vs wearables

• Because true N3 is defined electrophysiologically, claims of “more deep sleep” from consumer devices should be interpreted cautiously. Validation studies show fair-to-good detection of sleep vs wake, but stage classification can drift from PSG, especially night-to-night and in people with insomnia or fragmented sleep (de Zambotti 2019, Sleep; Menghini 2021, Nat Sci Sleep). Evidence: moderate.

Practical perspective

• If your goal is more restorative sleep, research suggests prioritizing behaviors that consolidate sleep (regular schedule, wind-down routine, light and caffeine timing), and exploring CBT-I if insomnia symptoms persist. Supplements may help with initiation (melatonin), relaxation and perceived sleep quality (magnesium varieties, chamomile/apigenin, passionflower), or overall time in bed (tart cherry). Evidence that any single supplement reliably and selectively increases N3 is currently limited.
• Bridging traditions: Botanicals like valerian, passionflower, and jujube seed have long been used to calm the nervous system. Modern research points to GABAergic and serotonergic pathways that plausibly support deeper, more consolidated sleep—mechanistic threads that complement traditional frameworks—even if stage-specific human data are still emerging.

Bottom line

• The strongest human evidence supports melatonin for sleep onset and circadian adjustment, not for boosting deep sleep proportion. Evidence: strong for onset; limited for N3.
• Magnesium (including glycinate) and glycine may improve relaxation, sleep quality, and next-day functioning; consistent, PSG-verified increases in N3 have not been established. Evidence: emerging for N3; moderate for subjective outcomes.
• Tart cherry juice may modestly extend total sleep time; effects on N3 remain unclear. Evidence: moderate for total sleep; unknown for N3.
• Traditional botanicals (valerian, passionflower, jujube seed) have supportive historical use and early clinical signals but lack robust architecture data. Evidence: traditional/emerging.
• CBT-I shows durable improvements in core insomnia outcomes and likely supports healthier overall architecture through better consolidation. Evidence: strong.
• If you monitor sleep stages with a wearable, be cautious in interpreting night-to-night changes in “deep sleep,” as device algorithms may not align with PSG.

References (selected)

• Ferracioli-Oda E et al. PLoS One. 2013.
• Auld F et al. Sleep Med Rev. 2017.
• Abbasi B et al. J Res Med Sci. 2012.
• Bannai M, Kawai N. J Pharmacol Sci. 2012.
• Yamadera W et al. Sleep Biol Rhythms. 2007.
• Peuhkuri K et al. Nutrients. 2012.
• Pigeon WR et al. J Med Food. 2010.
• Howatson G et al. Eur J Nutr. 2012.
• Leach MJ, Page AT. Cochrane Database Syst Rev. 2015.
• Ngan A, Conduit R. Phytother Res. 2011.
• Cao H et al. Medicine (Baltimore). 2020.
• Trauer JM et al. Ann Intern Med. 2015.
• Wu JQ et al. JAMA Intern Med. 2015.
• Edinger JD, Means MK. Chest. 2020.
• de Zambotti M et al. Sleep. 2019.